<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295945</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000459963</org_study_id>
    <secondary_id>UCSF-03423</secondary_id>
    <secondary_id>UCSF-H10588-24197-02</secondary_id>
    <nct_id>NCT00295945</nct_id>
  </id_info>
  <brief_title>Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer</brief_title>
  <official_title>Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the
      covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer
      surgery. It is not yet known whether epidural analgesia is more effective than
      patient-controlled analgesia in controlling pain in patients who have undergone surgery for
      gynecologic cancer.

      PURPOSE: This randomized clinical trial is studying epidural analgesia to see how well it
      works compared to patient-controlled analgesia in treating patients who have undergone
      surgery for gynecologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether the gradual weaning of an epidural opioid can shorten the duration of
           postoperative ileus, without worsening pain control, in patients who have undergone
           surgery for gynecologic cancer.

        -  Compare postoperative pain management in patients treated with perioperative epidural
           analgesia vs patient controlled analgesia.

        -  Compare time to ambulation, return of bowel function, and readiness for hospital
           discharge in patients treated with these pain management interventions.

        -  Compare the incidence of perioperative complications (e.g., bleeding, hypotension,
           thromboembolic events, pneumonia, wound infection, myocardial infection, or death) in
           patients treated with these pain management interventions.

      OUTLINE: This is a partially randomized, double-blind, parallel-group study. Patients choose
      between epidural analgesia or patient controlled analgesia (PCA) for perioperative pain
      management. Patients for whom an epidural is contraindicated receive a PCA. Patients are
      assigned to 1 of 2 treatment groups. Patients in group 1 are stratified according to bowel
      resection surgery (yes vs no) and prior abdominal surgery (yes vs no).

        -  Group 1 (epidural): Patients undergo placement of a thoracic epidural catheter followed
           by abdominal/pelvic surgery. Patients then begin an epidural infusion of ropivacaine
           hydrochloride and fentanyl immediately after surgery (postoperative day 0). Patients may
           also be supplemented with a patient controlled demand dose. The day after surgery
           (postoperative day 1), patients are randomized (as long as there is adequate pain
           control) to 1 of 2 epidural management arms.

             -  Arm I: Patients continue to receive the epidural infusion until they can be weaned
                to oral pain medication.

             -  Arm II: Patients undergo daily weaning of the fentanyl concentration of the
                epidural infusion.

        -  Group 2 (PCA): Patients begin PCA immediately after undergoing abdominal/pelvic surgery
           (postoperative day 0). Patients receive a demand schedule of hydromorphone IV until they
           can be weaned to oral pain medication.

      In both groups, the Gynecologic Oncology pain service may make adjustments to the epidural
      infusion or PCA for optimal pain management until the patient can be weaned to oral pain
      medication.

      PROJECTED ACCRUAL: A total of 224 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to return to bowel function at discharge</measure>
    <time_frame>Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score daily</measure>
    <time_frame>Days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">240</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pain</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>PCA</arm_group_label>
    <description>Patient-controlled intravenous analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCEA</arm_group_label>
    <description>Perioperative patient-controlled epidural analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl citrate</intervention_name>
    <arm_group_label>PCEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydromorphone hydrochloride</intervention_name>
    <arm_group_label>PCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine hydrochloride</intervention_name>
    <arm_group_label>PCEA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a gynecologic malignancy

          -  Scheduled to undergo open abdominal/pelvic surgery (i.e., laparotomy) on the
             gynecologic oncology service at the University of California San Francisco Medical
             Center

          -  No failed epidural catheters (for patients choosing epidural analgesia)

          -  No lumbar epidurals (for patients choosing epidural analgesia)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a gynecologic malignancy

          -  Scheduled to undergo open abdominal/pelvic surgery (i.e., laparotomy) on the
             gynecologic oncology service at the University of California San Francisco Medical
             Center

          -  No failed epidural catheters (for patients choosing epidural analgesia)

          -  No lumbar epidurals (for patients choosing epidural analgesia)

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee-may Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>perioperative/postoperative complications</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage I endometrial carcinoma</keyword>
  <keyword>stage II endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage I uterine sarcoma</keyword>
  <keyword>stage II uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>stage IA fallopian tube cancer</keyword>
  <keyword>stage IB fallopian tube cancer</keyword>
  <keyword>stage IC fallopian tube cancer</keyword>
  <keyword>stage IIA fallopian tube cancer</keyword>
  <keyword>stage IIB fallopian tube cancer</keyword>
  <keyword>stage IIC fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <keyword>stage IV fallopian tube cancer</keyword>
  <keyword>stage IA ovarian epithelial cancer</keyword>
  <keyword>stage IB ovarian epithelial cancer</keyword>
  <keyword>stage IC ovarian epithelial cancer</keyword>
  <keyword>stage IIA ovarian epithelial cancer</keyword>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IA ovarian germ cell tumor</keyword>
  <keyword>stage IB ovarian germ cell tumor</keyword>
  <keyword>stage IC ovarian germ cell tumor</keyword>
  <keyword>stage IIA ovarian germ cell tumor</keyword>
  <keyword>stage IIB ovarian germ cell tumor</keyword>
  <keyword>stage IIC ovarian germ cell tumor</keyword>
  <keyword>stage IIIA ovarian germ cell tumor</keyword>
  <keyword>stage IIIB ovarian germ cell tumor</keyword>
  <keyword>stage IIIC ovarian germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

